Activated microglia, which can be detected in vivo by 11C-PBR28 positron emission tomography (PET), represent a main component of MS pathology in the brain. Their role in the cerebellum is still unexplored, although cerebellar involvement in MS is frequent and accounts for disability progression.
Objectives:
We aimed at characterizing cerebellar neuroinflammation in MS patients compared to healthy subjects by combining 11C-PBR28 MRI-Positron Emission Tomography (MR-PET) with 7 Tesla (T) MRI and assessing its relationship with brain neuroinflammation and clinical outcome measures.
Methods:
Twenty-eight MS patients and 16 healthy controls underwent 11C-PBR28 MR-PET to measure microglia activation in normal appearing cerebellum and lesions segmented from 7 T scans. Patients were evaluated using the Expanded Disability Status Scale and Symbol Digit Modalities Test. 11C-PBR28 binding was assessed in regions of interest using 60–90 minutes standardized uptake values normalized by a pseudo-reference region in the brain normal appearing white matter. Multilinear regression was used to compare tracer uptake in MS and healthy controls and assess correlations with clinical scores.
Results:
In all cerebellar regions examined, MS patients showed abnormally increased tracer uptake, which correlated with cognitive and neurological disability.
Conclusion:
Neuroinflammation is widespread in the cerebellum of patients with MS and related to neurological disability and cognitive impairment.
AmatoMPPonzianiG.A prospective study on the prognosis of multiple sclerosis. Neurol Sci2000; 21: S831–S838.
2.
ErikssonMAndersenORunmarkerB.Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler2003; 9(3): 260–274.
3.
WeierKBanwellBCerasaA, et al. The role of the cerebellum in multiple sclerosis. Cerebellum2015; 14: 364–374.
4.
MagliozziRHowellOVoraA, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain2007; 130(Pt. 4): 1089–1104.
5.
HowellOWReevesCANicholasR, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain2011; 134(Pt. 9): 2755–2771.
6.
RissanenETuiskuJRokkaJ, et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195. J Nucl Med2014; 55(6): 939–944.
7.
GiannettiPPolitisMSuP, et al. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain2015; 138(Pt. 1): 110–119.
8.
HowellOWSchulz-TrieglaffEKCarassitiD, et al. Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. Neuropathol Appl Neurobiol2015; 41(6): 798–813.
9.
KreislWCFujitaMFujimuraY, et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage2010; 49: 2924–2932.
10.
ParkEGallezotJDDelgadilloA, et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: Test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging2015; 42(7): 1081–1092.
11.
MollNMRietschAMThomasS, et al. Multiple sclerosis normal-appearing white matter: Pathology-imaging correlations. Ann Neurol2011; 70(5): 764–773.
12.
FilippiMEvangelouNKangarluA, et al. Ultra-high-field MR imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry2014; 85: 60–66.
13.
FartariaMJO’BrienKSoregaA, et al. An ultra-high field study of cerebellar pathology in early relapsing-remitting multiple sclerosis using MP2RAGE. Invest Radiol2017; 52(5): 265–273.
14.
OwenDRYeoAJGunnRN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab2012; 32(1): 1–5.
15.
HerranzEGianniCLouapreC, et al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol2016; 80(5): 776–790.
16.
PolmanCHReingoldSCBanwellB, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
17.
KurtzkeJF.Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33(11): 1444–1452.
18.
ParmenterBATestaSMSchretlenDJ, et al. The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc2010; 16(1): 6–16.
19.
KolbAWehrlHFHofmannM, et al. Technical performance evaluation of a human brain PET/MRI system. Eur Radiol2012; 22(8): 1776–1788.
20.
Izquierdo-GarciaDHansenAEForsterS, et al. An SPM8-based approach for attenuation correction combining segmentation and nonrigid template formation: Application to simultaneous PET/MR brain imaging. J Nucl Med2014; 55(11): 1825–1830.
21.
LouapreCGovindarajanSTGianniC, et al. Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T. Neurology2015; 85(19): 1702–1709.
22.
HannestadJGallezotJDSchafbauerT, et al. Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates. Neuroimage2012; 63(1): 232–239.
23.
CalabreseMMattisiIRinaldiF, et al. Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis. J Neurol Neurosurg Psychiatry2010; 81(4): 401–404.
24.
KutzelniggAFaber-RodJCBauerJ, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol2007; 17(1): 38–44.
25.
HerranzEHookerJMIzquierdo-GarciaD, et al. Reply. Ann Neurol2017; 81(2): 324–325.
26.
KutzelniggALucchinettiCFStadelmannC, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain2005; 128(Pt. 11): 2705–2712.
27.
OhUFujitaMIkonomidouVN, et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol2011; 6(3): 354–361.
28.
MagliozziRHowellOWReevesC, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol2010; 68(4): 477–493.
29.
DeppeMTabelowKKramerJ, et al. Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration. Mult Scler2016; 22(1): 73–84.
30.
ValentinoPCerasaAChiriacoC, et al. Cognitive deficits in multiple sclerosis patients with cerebellar symptoms. Mult Scler2009; 15(7): 854–859.
31.
WeierKPennerIKMagonS, et al. Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis. PLoS One2014; 9(1): e86916.
32.
TobyneSMOchoaWBBireleyJD, et al. Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis. Mult Scler2017; 24(13):1687–1695.
33.
ProsperiniLSbardellaERazE, et al. Multiple sclerosis: White and gray matter damage associated with balance deficit detected at static posturography. Radiology2013; 268(1): 181–189.
34.
RizzoGVeroneseMToniettoM, et al. Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities. J Cereb Blood Flow Metab. Epub ahead of print 1 January 2017. DOI: 10.1177/0271678X17742004.
